Page 199 of 291 · 8,722 total

patent null · Aug 2, 2024

DISH Network L.L.C. et al. v.Entropic Communications LLC

· IPR2024-00555

DISH Network L.L.C. initiated an IPR challenging patent 8320566 owned by Entropic Communications LLC, arguing that the claims are obvious under 35 U.S.C. § 103. The petitioner relies on multiple combinations of prior art references, including Cleveland/Hayashino and Scheim/Tzannes, to demonstrate non-patentability in the field of OFDMA/Scrambling.

patent denied · Aug 2, 2024

Nexus Pharmaceuticals LLC v.Exela Pharma Sciences, LLC

· PGR2024-00016

Nexus Pharmaceuticals' PGR challenge against Exela Pharma Sciences was denied institution because the arguments regarding enablement, written description, and obviousness were largely identical to those previously presented during prosecution. The Board found that the Patent Owner successfully demonstrated how process controls overcome prior rejections, leading to a denial of the petition under § 325(d).

patent instituted · Aug 2, 2024

Juniper Networks, Inc. v.Monarch Networking Solutions LLC

· IPR2024-00561

Juniper Networks successfully petitioned to institute IPR against Monarch Networking Solutions LLC regarding packet switching claims (Claims 1 and 6). The Board found sufficient evidence of obviousness over combinations of prior art references, including Wainner/Bocci and Kamite/Bocci.

patent denied · Aug 2, 2024

DISH Network L.L.C. et al. v.Entropic Communications LLC

· IPR2024-00555

DISH Network L.L.C.'s IPR petition against Entropic Communications LLC's '566 patent was denied by the PTAB, finding no reasonable likelihood of prevailing on any claim. The Board rejected all asserted grounds under 35 U.S.C. § 103 regarding obviousness over various prior art combinations in OFDMA/Spectrum Sharing technology.

patent final · Aug 2, 2024

Juniper Networks, Inc. v.Monarch Networking Solutions LLC

· IPR2024-00561

The PTAB issued a Final Written Decision finding that claims 1 and 6 of the patent were unpatentable over prior art references Wainner and Bocci. The Board agreed with the Petitioner's argument that combining these references rendered the claimed method obvious, particularly regarding shared link functionality in pseudo-wires.

patent · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

Serendia seeks Director Review to overturn the Board’s institution of an IPR against its dermatology device patent after the ITC affirmed the patent’s validity, arguing the Board abused discretion and that extraordinary circumstances exist.

patent terminated or settled · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

EndyMed Medical and Serendia have settled their dispute over U.S. Patent 9,480,836 and jointly moved to terminate the inter partes review. The Board is asked to dismiss the proceeding before any oral hearing or final decision.

patent terminated or settled · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

Endymed Medical and Serendia settled their inter partes review of U.S. Patent 9,480,836, leading the PTAB to terminate the proceeding under 35 U.S.C. § 317.

patent terminated or settled · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

The PTAB granted a joint motion to terminate the IPR for Jeisys Medical Inc. after the parties settled their dispute. The settlement agreement was ordered to be kept confidential, and the proceeding remains open only for EndyMed petitioners.

patent · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

Ilooda and Serendia filed a joint motion to terminate Ilooda's participation in an IPR over a dermatology device patent, citing a settlement that resolves the dispute.

patent terminated or settled · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

Jeisys Medical and Serendia have settled their dispute over U.S. Patent 9,480,836 and jointly moved to terminate the inter partes review. The Board is asked to end the proceeding before any substantive briefing or hearing.

patent terminated or settled · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Serendia and Jeisys Medical settled their IPR dispute over U.S. Patent 9,320,536, leading the PTAB to terminate the proceeding.

patent · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

EndyMed Medical and Serendia, LLC jointly filed a request to keep their settlement agreement confidential under statutory provisions, separating it from the IPR file.

patent terminated or settled · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

EndyMed Medical Ltd. and EndyMed Medical Inc. jointly moved to terminate IPR2024-00384 after reaching a settlement with patent owner Serendia, LLC. The Board was asked to end the proceeding before any oral hearing or final decision.

patent · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Serendia requests Director Review to terminate IPR2024-00384, arguing the Board improperly expedited institution of time‑barred petitions despite a pending ITC validity finding. The petition cites the rescinded Fintiv memo and extraordinary circumstances to seek dismissal.

patent terminated or settled · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Jeisys Medical and Serendia have settled their IPR dispute over U.S. Patent 9,320,536 and jointly moved to terminate the proceeding under 35 U.S.C. §317.

patent · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Ilooda and Serendia have settled their dispute over a dermatology‑device patent and jointly moved to terminate Ilooda’s participation in the pending IPR, requesting the settlement remain confidential.

patent · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Jeisys Medical and Serendia have jointly filed a request with the PTAB to keep their settlement agreement confidential under statutory confidentiality rules. The filing cites 35 U.S.C. §317(b) and related CFR provisions.

patent terminated or settled · Aug 1, 2024

Samsung Electronics Co., Ltd. et al. v.Advanced Coding Technologies, LLC

· IPR2024-00374

Samsung Electronics and Advanced Coding Technologies have reached a confidential settlement over U.S. Patent 8,090,025 and jointly moved to terminate the inter partes review.

patent terminated or settled · Aug 1, 2024

Samsung Electronics Co., Ltd. et al. v.Advanced Coding Technologies, LLC

· IPR2024-00372

Samsung and Advanced Coding Technologies settled their IPR dispute over patent 10,218,995. The Board granted the joint motion to terminate the proceeding and treated the settlement agreement as confidential.

patent terminated or settled · Aug 1, 2024

Samsung Electronics Co., Ltd. et al. v.Advanced Coding Technologies, LLC

· IPR2024-00372

Samsung and video‑codec startup Advanced Coding Technologies have settled their dispute over a moving‑picture encoding patent, filing a joint motion to terminate the inter partes review.

patent · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

Serendia and EndyMed jointly filed a request to keep their settlement agreement confidential under federal law, seeking to separate it from the patent record.

patent · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

Serendia and Jeisys Medical jointly filed a request to keep their settlement agreement confidential under 35 U.S.C. §317(b), seeking to separate it from the patent record.

patent · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Jeisys Medical settled with SHEnB and Cartessa respondents during its IPR against Serendia, leading to a motion to suspend the schedule.

patent terminated or settled · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

The Board granted a joint motion to terminate the IPR only for Jeisys Medical Inc. after a settlement with Serendia, while EndyMed remains as a petitioner. The settlement agreement was ordered confidential.

patent terminated or settled · Aug 1, 2024

Samsung Electronics Co., Ltd. et al. v.Advanced Coding Technologies, LLC

· IPR2024-00374

Samsung and Advanced Coding Technologies settled their IPR dispute over patent 8,090,025, leading the PTAB to terminate the proceeding. The settlement agreement was treated as confidential business information.

patent instituted · Aug 1, 2024

Bowmar Archery LLC v.Futtere, Matthew

· IPR2024-00401

Bowmar Archery LLC successfully petitioned the PTAB to institute review of claims in Patent No. 8043177, challenging its validity based on anticipation and obviousness grounds. The petition cites numerous prior art references related to broadhead technology, arguing that the claimed structural elements are already known in the field.

patent null · Aug 1, 2024

AT&T Corp. et al. v.Daingean Technologies Ltd.

· IPR2024-00402

A coalition of major telecom companies (AT&T, Ericsson, Nokia, T-Mobile) filed a Petition challenging Daingean Technologies' patent 10841958. The challenge asserts that the claims are anticipated or obvious based on prior art references Lee and Brismar.

patent null · Aug 1, 2024

Ilooda Co., Ltd. et al. v.Serendia, LLC

· IPR2024-00386

Petitioner Ilooda Co., Ltd. and Jeisys Medical Inc. challenged the validity of Serendia, LLC's '836 patent in a PTAB petition. The petitioner asserts that multiple claims are obvious under 35 U.S.C. § 103 based on combinations of prior art references like Ganz, Livneh, Hantash, and Lee.

patent instituted · Aug 1, 2024

Jeisys Medical Inc. et al. v.Serendia, LLC

· IPR2024-00384

Petitioner Jeisys Medical Inc. successfully petitioned the PTAB to institute review of U.S. Patent No. 9,320,536 regarding dermatological treatment devices. The petition asserts compelling grounds for unpatentability under both 35 U.S.C. §§ 102 and 103 based on multiple prior art references.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →